OncoMatch/Clinical Trials/NCT05656573
CART-PSMA Cells for Advanced Prostate Cancer
Is NCT05656573 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CART-PSMA cells for prostate cancer.
Treatment: CART-PSMA cells — This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 overexpression (as demonstrated by immunohistochemistry analysis or other methods)
Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: gene therapy
Patients who are already undergoing other gene therapy
Cannot have received: cell therapy
Patients who are already undergoing other ... cell therapy
Cannot have received: other clinical drug trials
Patients who are already undergoing other clinical drug trials
Lab requirements
Blood counts
hemoglobin concentration ≥80g/L
Kidney function
serum creatinine < 2.0 mg/dl
Liver function
ALT < 3x ULN, AST < 3x ULN, serum bilirubin and alkaline phosphatase < 2x ULN
Cardiac function
left ventricular ejection fraction (LVEF) ≥50%
Adequate liver function, specifically alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN), aspartate transferase (AST)< 3 times of ULN, serum bilirubin and alkaline phosphatase < 2 times of ULN. Adequate renal function, specifically serum creatinine < 2.0 mg/dl. Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%. Hemoglobin concentration ≥80g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify